NextGenSIT: An Off-the-Shelf and On-Demand Product for Biological Control of Aedes aegypti Mosquitoes

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R44AI195189-01

Grant search

Key facts

  • Disease

    N/A

  • Start & end year

    2025
    2026
  • Known Financial Commitments (USD)

    $302,537
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PI. Nikolay Kandul
  • Research Location

    United States of America
  • Lead Research Institution

    SYNVECT, INC.
  • Research Priority Alignment

    N/A
  • Research Category

    Animal and environmental research and research on diseases vectors

  • Research Subcategory

    Vector control strategies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The overarching objective of this project is to finalize the development and commercialization of Synvect's innovative NextGenSIT technology for Aedes aegypti mosquito control. This transformative genetic engineering solution combines precision-guided CRISPR gene knockouts with scalable deployment methods to address the urgent global need for eco-friendly, effective, and cost efficient mosquito control. By targeting mosquito populations responsible for spreading diseases such as dengue, yellow fever, and Zika, this project aims to establish a new standard for combating vector-borne diseases while advancing regulatory readiness and market viability. Aim 1 focuses on finalizing the genetic components for the Ae. aegypti NextGenSIT eggs, leveraging CRISPR-mediated knockouts of specific genes to ensure the production of competitive, sterile males at scale. This work involves rigorous testing and optimization to select the most effective genetic reagents for deployment. Aim 2 emphasizes developing and validating deployment strategies for NextGenSIT eggs. This includes optimizing the egg-to-male transformation in the environment by deploying the produced eggs and reusable egg-to-adult boxes to create a user-friendly and cost-effective product for large-scale application. Aim 3 transitions from laboratory validation to semi-field and small-scale open-air pilots in Florida and Texas, assessing deployment parameters and achieving a 90% reduction in mosquito populations under controlled yet realistic conditions. These interim trials will bridge the gap between lab results and real-world deployment, providing critical data on scalability, environmental adaptability, and operational efficacy. Aim 4 expands on this foundation by conducting larger open-air pilots with government and commercial partners, validating the real-world impact of NextGenSIT and securing the Environmental Protection Agency (EPA) approval. This phase is critical for demonstrating product value, aligning with customer needs, and converting at least 50% of pilot participants into long-term customers. The expected outcomes of this project include the development of a scalable, eco-friendly mosquito control solution with proven efficacy in reducing vector populations, securing EPA approval, and establishing Synvect as a trusted leader in vector control technologies. By bridging lab innovation with real-world application, this initiative will create a robust pathway for commercialization and set a new benchmark in combating vector-borne diseases globally.